- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Celltrion's COVID-19 Antibody Treatment Moves Into Phase 2/3 Trial
Celltrion moves another step forward in its bid to get a coronavirus disease 2019 (COVID-19) treatment on the market.
After receiving positive results from a phase 1 trial for its coronavirus disease 2019 (COVID-19) monoclonal antibody treatment (CT-P59), Incheon, Republic of Korea–based Celltrion Healthcare has received approval to initiate a phase 2/3 trial.
“Given that COVID-19 represents a significant global threat to life, there is an urgent need to identify treatments that can help stabilize our response to the pandemic. The initiation of the global phase II/III pivotal trial of CT-P59 is an important step forward,” said Sang Joon Lee, PhD, senior executive vice president at Celltrion, in a statement.
The news comes as Celltrion’s infliximab biosimilar (Remsima) is being tested in the phase 2 CATALYST trial to assess its efficacy in treating patients with inflammation linked to COVID-19 during hospitalization.
The phase 2/3 trial will be a global trial evaluating the safety and efficacy of CT-P59 in patients with mild-to-moderate symptoms related to COVID-19.
Celltrion, primarily a biosimilar developer and manufacturer, said it expects to have primary results for the phase 2 portion of the study by the end of 2020.
The company has filed an investigational new drug application for the trial in 6 countries, including the Republic of Korea, the United States, and Spain.
Celltrion said it plans to enroll more than 1000 patients in the multinational trial. Assuming the phase 2/3 trial yields positive results, the company expects to be able to apply for emergency use authorization.
“Celltrion has begun manufacturing the process validation batch of CT-P59 and plans to increase manufacturing capabilities to meet the current global and domestic demand for the anti-COVID-19 monoclonal antibody treatment candidate,” the company said in a statement.
In addition to the phase 2/3 trial, Celltrion has initiated an ongoing in-human global phase 1 trial for CT-P59 in patients with mild cases of COVID-19. The company said it also plans to investigate whether CT-P59 is effective as a preventive treatment for those who are in close contact with patients with COVID-19.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
